Researchers have developed a method of reducing pain-associated behaviors through the creation of decoy molecules that prevent pain after injury.
Through RNA-based medicine, researchers have developed a method of reducing pain-associated behaviors through the creation of decoy molecules that prevent pain after injury, according to a study published in Nature Communications.
“Pain is a pervasive and devastating problem,” Zachary Campbell, PhD, director of the Laboratory of RNA Control at the University of Texas at Dallas, said in a statement. “It’s the most prominent reason why Americans seek medical attention. Poorly treated pain causes enormous human suffering, as well as a tremendous burden on medical care systems and our society.”
Campbell conducted the research alongside Ted Price, PhD, associate professor from the Neurobiology Research Group, and Michael Burton, PhD, assistant professor from the School of Behavioral and Brain Sciences.
Campbell along with other researchers believed that pain could be blocked by interrupting the pain-protein synthesis that is coded in mRNA facilitates within the genome. This will reduce inflammation and impair pain behaviors. The team designed an RNA mimic that was injected on mouse models which showed positive results on reducing pain.
“We’re manipulating one step of protein synthesis,” Campbell explained. “Our results indicate that local treatment with the decoy can prevent pain and inflammation brought about by a tissue injury.”
The researchers found great difficulty in working with the RNA-based compound as the rapid metabolism of the molecules had them degrading quickly within the cells. However, the study found more information on nociceptors, specialized nerve cells that communicate with the brain in response to thermal, chemical, or mechanical stimuli.
Campbell also finds that this new therapy is a step in the right direction by moving away from prescribed pain medications that affect the reward center of the brain. “The ongoing opioid crisis highlights the need for pain treatments that don’t create addictions,” he said. “Hopefully, this is a step in that direction.”
This RNA mimic technology is the first of its kind that will be able to treat a variety of medical issues in the future.
“To the best of our knowledge, this is the first attempt to create a chemically stabilized mimic to competitively inhibit RNA to disrupt RNA-protein interactions,” he said. “Our approach suggests that targeting those interactions may provide a new source of pharmacological agents. This proof of concept allows us to open a whole new area of science by virtue of the route that we’re attacking it.”
References
Barragán-Iglesias P, Lou TF, Bhat VD, et al. Inhibition of Poly(A)-binding protein with a synthetic RNA mimic reduces pain sensitization in mice. Nat Commun. 2018;9(1). doi:10.1038/s41467-017-02449-5.
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Prediction Model Identified Risk Factors for ED Visits in Patients With Lung Cancer
December 7th 2023A risk prediction model that was based on machine learning could help to make resource utilization more efficient by correctly predicting emergency department (ED) visits in patients with lung cancer.
Read More
Understanding the Unmet Need for Therapies to Treat Rare Bile Duct Cancer
May 24th 2022On this episode of Managed Care Cast, we bring you an excerpt of an interview with a co-chair of the 2022 Cholangiocarcinoma Foundation (CCF) annual conference, held earlier this year, about the significant unmet therapy needs facing most patients with this rare cancer.
Listen
New Investigation Analyzes Magnetic Resonance Measures of DMD for Disease Progression
December 7th 2023Investigators evaluated longitudinal MRI and spectroscopy outcomes and ambulatory function among 180 patients with Duchenne muscular dystrophy (DMD) to establish the utility and reproducibility of magnetic resonance measures of muscle quality at different disease stages.
Read More
Eculizumab Biosimilar ABP 959 Demonstrates Similarity to Reference in Patients With PNH
December 6th 2023ABP 959, an eculizumab biosimilar in development, has demonstrated similar efficacy and pharmacokinetics to the reference product for patients with paroxysmal nocturnal hemoglobinuria (PNH), according to research at the 2023 American Society of Hematology Annual Meeting.
Read More